

# **RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY**

**Cardiology 2017 – professional education, science and  
innovations**

## **SCEINTIFIC PROGRAMME**

**October 24-27, 2017**

**Saint-Petersburg**

**24.10.17**

**Conference Hall №1 (E8-E9)**

**09.00–10.30**

**Symposium**

**«Innovations in cardiovascular risk reduction»**

**(supported by Boehringer Ingelheim)**

**Chairperson: Shlyakhto E.** (Saint-Petersburg)

**Shlyakhto E.** (Saint-Petersburg). Prevention of cardiometabolic stroke in the Russian clinical practice: GLORIA – AF data.

**Baranova E.** (Saint-Petersburg). Patient with AF and ACS. New options - the results of RE-DUAL PCI study.

**Yanishevsky S.** (Saint-Petersburg). Patient with AF and comorbidity: from innovation to clinical decision making.

**Kobalava Z.** (Moscow). Focus on the cardioprotective benefits of treatment of patients with T2DM.

**24.10.17**

**Conference Hall №5 (D3)**

**09.00–10.30**

**Symposium**

**«A tale of the lost time»**

**(supported by Teva)**

**Chairperson: Koziolova N. (Perm)**

**Koziolova N. (Perm).** Optimal drug therapy - a modern strategy of life prolongation in patients with IHD.

**Obrezan A. (Saint-Petersburg).** Long-term therapy as the basis of life prolongation in cardiovascular patients.

**24.10.17**

**Conference Hall №3 (D1)**

**11.00–12.30**

**Symposium**

**«Consistency of therapy at all stages of ACS patient management»**

**(supported by AstraZeneca)**

**Chairperson: Vasilieva E. (Moscow)**

**Lebedeva A.** (Moscow). Organization of medical care in ACS in the first 24 hours after the event: best practices.

**Yakovlev A.** (Saint-Petersburg). Double antiplatelet therapy for the first 12 months after ACS.

**Boldueva S.** (Saint-Petersburg). A patient with a high ischemic risk after MI: who needs DAT for more than 12 months?

**24.10.17**

**Conference Hall №5 (D3)**

**11.00–12.30**

**Symposium**

**«Myocardial infarction 2017»**

**(supported by Sanofi)**

**Chairperson: Ruda M. (Moscow)**

**Barbarash O. (Kemerovo).** Non-STEMI management.

**Yavelov I. (Moscow).** MI in patients with no coronary artery obstructive lesions.

**Averkov O. (Moscow).** STEMI management.

**24.10.17**

**Conference Hall №6 (D4)**

**11.00–12.30**

### **Symposium**

**«Current options in prevention of cardiovascular events»**

**(supported by Pfizer)**

### **On-line broadcasting**

**Chairpersons: Mareev V. (Moscow), Karpenko M. (Saint-Petersburg)**

**Karpenko M.** (Saint-Petersburg). Anticoagulation therapy in AF patients with different risks of stroke and bleeding.

**Mareev V.** (Moscow). Clinical guidelines and clinical practice or «life is richer than textbooks».

**Kobalava Z.** (Moscow). Expanding horizons: anticoagulants in AF patients in the clinical practice.

**Mareev V.** (Moscow). Smoking as the most modifiable risk factor of MI and stroke. Ways to solve the problem.

**24.10.17**

**Conference Hall №7 (B1)**

**11.00–12.30**

**Symposium**

**«Sartans: is there a difference? The perspective of a cardiologist, a neurologist and a clinical pharmacologist**

**(supported by Teva)**

**Chairperson: Glezer M. (Moscow)**

**Glezer M. (Moscow).** The agony of choosing.

**Zyryanov S. (Moscow).** From clinical pharmacology to clinical outcome.

**Zyryanov S. (Moscow).** Is BP lowering equal to brain protection?

**24.10.17**

**Conference Hall №8 (B2)**

**11.00–12.30**

**Symposium**

**«Cytoprotectors and cardiovascular disease: options and prospects»**

**(supported by Grindex)**

**Chairperson: Mikhin V. (Kursk)**

**Mikhin V. (Kursk).** Cytoprotectors in acute and chronic coronary diseases.

**Shishkova V. (Moscow).** Cerebro-vascular disorders in cardiovascular patients.



**24.10.17**

**Conference Hall №2 (E7)**

**13.00–14.30**

**Symposium**

**«Methodology of new oral anticoagulants selection for patients with atrial fibrillation»**

**(supported by Bayer)**

**Chairperson: Shlyakhto E.** (Saint-Petersburg)

**Arutyunov G.** (Moscow). How does a Russian patient with atrial fibrillation differ from patients enrolled in randomized clinical trials? How to interpret clinical trials data in the clinical practice?

**Lopatin Yu.** (Volgograd). A patient with atrial fibrillation and diabetes: what to pay attention to when selecting anticoagulation therapy?

**Gilyarov M.** (Moscow). Management of patients with atrial fibrillation and chronic kidney disease.

**Take home message.**

**24.10.17**

**Conference Hall №3 (D1)**

**13.00–14.30**

**Symposium**

**«The latest trends in treatment of AH patients: ambitious goals and new options in the clinical practice»**

**(supported by Takeda)**

**Chairperson: Kobalava Z.** (Moscow)

**Karpov Yu.** (Moscow). How will target BP be changing after the latest trials?

**Kobalava Z.** (Moscow). Standards vs ACE in target AH patients therapy: what is the basis of selection?

**Nedogoda S.** (Volgograd). 24-hour BP control as the most important factor of prognosis improvement in in AH patients: fixed Edarbi Clo combinations.

**24.10.17**

**Conference Hall №4 (D2)**

**13.00–14.30**

**Symposium**

**«Atrial fibrillation and anticoagulant therapy in various clinical situations»**

**(supported by Boehringer Ingelheim)**

**Chairperson: Tkacheva O. (Moscow)**

**Novikova N. (Moscow).** Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome.

**Vinogradov O. (Moscow).** Anticoagulant therapy in patients after cardioembolic stroke.

**Tkacheva O. (Moscow).** Anticoagulant therapy in elderly patients.

**Zotova I. (Moscow).** A patient with atrial fibrillation and comorbidities: choosing a safe anticoagulant.

**24.10.17**

**Conference Hall №5 (D3)**

**13.00–14.30**

**Symposium**

**«Myths and reality. Risk of cardiovascular complications in a comorbid patient»**

**(supported by Egis)**

**Chairperson: Martsevich S. (Moscow)**

**Averin E. (Moscow).** Myths and reality: a review of the world experience in AH treatment.

**Martsevich S. (Moscow).** New options in correcting cardiovascular complications risk.

**Kurasov E. (Saint-Petersburg).** Anxiety-depressive disorders and arterial hypertension: a myth or reality.

**24.10.17**

**Conference Hall №6 (D4)**

**13.00–14.30**

**Symposium**

**«Safety, efficacy and simplicity of therapy – three whales, on which a polymorbid patient treatment is based»**

**(supported by Teva)**

**Chairperson: Koziolova N. (Perm)**

**Chestnikova A.** (Rostov-on-Don). Polymorbidity and polypharmacy - two sides of the same coin.

**Koziolova N.** (Perm). Drugs interaction: perspective of a patient and a doctor.

**Tarlovskaya E.** (Nizhny Novgorod). How to increase adherence to therapy in a cardiac patient.

**24.10.17**

**Conference Hall №8 (B2)**

**13.00–14.30**

### **Symposium**

**«CV risk reduction as the most important factor of life expectancy increase»**

**(supported by Pfizer)**

### **Recording**

**Chairpersons: Konradi A.** (Saint-Petersburg), **Ostroumova O.** (Moscow)

**Konradi A.** (Saint-Petersburg). AH and dyslipidemia as two strategic targets of primary and secondary cardiovascular prevention.

**Ostroumova O.** (Moscow). Effective BP reduction - not the final goal but one of the ways to improve prognosis.

**Sergienko I.** (Moscow). The efficacy and safety of statin therapy: no compromise.

**24.10.17**

**Conference Hall №1 (E8-E9)**

**15.00–16.30**

**Dialogue of experts**

**«How to improve outcomes of pulmonary artery thromboembolia treatment?»**

**(supported by Bayer)**

**Chairperson: Perepech N. (Saint-Petersburg)**

**Duplyakov D. (Samara).** Pulmonary artery thromboembolia managemt based on risk stratification.

**Khasanov N. (Kazan).** Choice of antocoagulation therapy in separate patients with high risk of repeated pulmonary artery thromboembolia and/or hemorrhages.

**Duplyakov D. (Samara).** Therapy of pulmonary artery thromboembolia in real life. What lessons can we get from observations and registries?

**Khasanov N. (Kazan).** Long-term prevention of repeated pulmonary artery thromboembolia. Any place for aspirin?

**Discussion. Questions and answers.**

**24.10.17**

**Conference Hall №2 (E7)**

**15.00–16.30**

**Symposium**

**«ARNI – Angiotensin Receptor Neprilysin Inhibitors — a new class of CHF treatment»**

**(supported by Novartis)**

**Chairpersons: Mareev V. (Moscow), Nedoshivin A. (Saint-Petersburg)**

**Mareev V. (Moscow).** Neurohumoral systems balance restoration – a modern view on CHF therapy. Renewed guidelines on CHF diagnosis and treatment.

**Discussion. Nedoshivin A. (Saint-Petersburg), Kobalava Z. (Moscow), Lopatin Yu. (Volgograd), Mareev V. (Moscow).**

**Lopatin Yu. (Volgograd).** Initiation of therapy and ARNI effectiveness in various patient groups.

**Discussion. Nedoshivin A. (Saint-Petersburg), Kobalava Z. (Moscow), Lopatin Yu. (Volgograd), Mareev V. (Moscow).**

**Kobalava Z. (Moscow).** ARNI in clinical practice – real life experience.

**Discussion. Nedoshivin A. (Saint-Petersburg), Kobalava Z. (Moscow), Lopatin Yu. (Volgograd), Mareev V. (Moscow).**



**24.10.17**

**Conference Hall №5 (D3)**

**15.00–16.30**

**Symposium**

**«A moderate and high risk patient: neoclassicism in the clinical practice»**

**(supported by Gedeon Richter)**

**Chairperson: Podzolkov V. (Moscow)**

**Podzolkov V. (Moscow).** Guidelines and the clinical practice: is harmony possible?

**Kislyak O. (Moscow).** Dyslipidemia correction and cardiovascular complications prevention in moderate-risk patients.

**Protasov K. (Irkutsk).** When  $2 + 1 > 3$ : a new solution in treatment of hypertension and atherosclerosis.

**24.10.17**

**Conference Hall №6 (D4)**

**15.00–16.30**

**Symposium**

**«Indirect anticoagulants in a new drug era»**

**(supported by Takeda)**

**Chairpersons: Zateischikov D.** (Moscow), **Vavilova T.** (Saint-Petersburg)

**Zateischikov D.** (Moscow). Long-term intake of anticoagulants 2017.

**Zotova I.** (Moscow). Warfarin in current cardiology practice.

**Vavilova T.** (Saint-Petersburg). Achievements and problems in organization of anticoagulation therapy monitoring. Saint-Petersburg experience.

**24.10.17**

**Conference Hall №8 (B2)**

**15.00–16.30**

**Symposium**

**«Cardiovascular complications of NSAIDs: time to reconsider»**

**(supported by Pfizer)**

**Chairpersons: Karpov Yu.** (Moscow), **Rebrov A.** (Saratov)

**Novikova D.** (Moscow). Effect of NSAIDs on cardiovascular system: hidden threat?

**Rebrov A.** (Saratov). Cardiovascular disease and long-term intake of NSAIDs.

**Karpov Yu.** (Moscow). Reducing the risk of cardiovascular complications of NSAIDs intake is possible.

**25.10.17**

**Conference Hall №5 (D3)**

**09.00–10.30**

**Symposium**

**«Standards of anti-platelet therapy: clinical pharmacology and the Russian reality»**

**(supported by Takeda)**

**Chairperson: Glezer M. (Moscow)**

**Ageev F. (Moscow).** Review of international guidelines on anti-platelet therapy: role of aspirin.

**Glezer M. (Moscow).** Unsolved issues in anti-platelet therapy in complicated cases.

**Zyryanov S. (Moscow).** How to avoid resistance and side effects in anti-platelet therapy? Pharmacokinetic and pharmacodynamic basis of the processes.

**25.10.17**

**Conference Hall №6 (D4)**

**09.00–10.30**

**Symposium**

**«Gender and personalized approaches to AH therapy in cardiology practice»**

**(Joint session with the Russian Scientific Medical Society of Internists)**

**(supported by Sanofi)**

**Chairpersons: Karpov Yu.** (Moscow), **Podzolkov V.** (Moscow)

**Karpov Yu.** (Moscow). Very high risk patients: guidelines and clinical practice.

**Podzolkov V.** (Moscow). Renin-angiotensin-aldosterone system blockade: just BP lowering?

**Napalkov D.** (Moscow). Personalized approach to statin therapy.

**25.10.17**

**Conference Hall №7 (B1)**

**09.00–10.30**

**Symposium**

**«Beta blockers in clinical practice: is everything known to a practical doctor?»**

**(supported by Egis)**

**Chairpersons: Martsevich S. (Moscow), Nebieridze D. (Moscow)**

**Martsevich S. (Moscow).** Evidence base of beta-blockers and real clinical practice.

**Nebieridze D. (Moscow).** The existing stereotypes around beta blockers.

**Averin E. (Moscow).** Topical issues of using beta blockers in various clinical situations.

**25.10.17**

**Conference Hall №8 (B2)**

**09.00–10.30**

**Symposium**

**(supported by Bayer)**

**Chairpersons:**

**25.10.17**

**Conference Hall №1 (E8-E9)**

**11.00–12.30**

**Symposium**

**«Redefining possible»**

**(supported by Sanofi)**

**Simultaneous translation**

**Chairpersons: Ezhov M. (Moscow), Karpov Yu. (Moscow)**

**Yakovlev A. (Saint-Petersburg).** LDL-cholesterol reduction in patients with very high cardiovascular risk.

**Karpov Yu. (Moscow).** Innovative concept of PCSK9 inhibition for LDL-cholesterol control.

**Ezhov M. (Moscow).** ODYSSEY Programme: focus on patients with very high cardiovascular risk.

**All experts.** Questions and Answers.



**25.10.17**

**Conference Hall №2 (E7)**

**11.00–12.30**

**Symposium**

**«Prevention of cardiovascular complications in CAD patients: status quo and new options»**

**(supported by Takeda)**

**Chairpersons: Arutyunov G. (Moscow), Perepech N. (Saint-Petersburg)**

**Perepech N. (Saint-Petersburg).** Improving outcomes in CAD patients: analysis of guidelines.

**Orlova Ya. (Moscow).** Secondary prevention of cardiovascular events: any results in the real-life practice?

**Arutyunov G. (Moscow).** Polypill as an innovative strategy to improve effectiveness of CAD therapy.

**25.10.17**

**Conference Hall №3 (D1)**

**11.00–12.30**

**Symposium**

**«Foundation of very high risk patients therapy»**

**(supported by AstraZeneca)**

**Chairpersons: Kobalava Z.** (Moscow), **Susekov A.** (Moscow), **Mareev V.** (Moscow), **Fomin I.** (Nizhny Novgorod)

**Susekov A.** (Moscow). Strengthen the fortress: highly intensive statin therapy in very high risk patients.

**Kobalava Z.** (Moscow). Fortification issues: safety of statins.

**Mareev V.** (Moscow). How to build for long: statin therapy.

**Fomin I.** (Nizhny Novgorod). Beta-blocker as a universal instrument for cardiovascular treatment.

**25.10.17**

**Conference Hall №7 (B1)**

**11.00–12.30**

**Symposium**

**«Current technologies and devices in arrhythmology»**

**(supported by Cardiomedics/Boston Scientific)**

**Chairpersons:**

**Mikhailov E.** (Saint-Petersburg). Cardiac contractility modulation in heart failure: what can we count for?

**Lebedev D.** (Saint-Petersburg). Subcutaneous ICD: a new standard in sudden cardiac death prevention?

... Cardiac resynchronization devices with a quadripolar left ventricle lead. What are the advantages?

**Romanov A.** (Novosibirsk). MRI compatible devices: what is really important?

**Krivolapov C.** (Tomsk). Endocardial lead extraction – how to reveal a problem and what to do with it?

**25.10.17**

**Conference Hall №8 (B2)**

**11.00–12.30**

### **Symposium**

**«Theory and practical consideration of PE treatment»**

**(supported by Pfizer)**

**Chairpersons: Andreev D. (Moscow), Obrezan A. (Saint-Petersburg)**

**Obrezan A.** (Saint-Petersburg). Anticoagulant therapy for acute PE: impact on life and prognosis.

**Andreev D.** (Moscow). What is important in management of a patient after PE. Aspects of prolonged thromboprophylaxis: when, what and why.

**Obrezan A.** (Saint-Petersburg), **Andreev D.** (Moscow). Clinical case: succession management of a patient with PE from an acute episode to prolonged treatment and further prevention.

**25.10.17**

**Conference Hall №11 (A4-A5)**

**11.00–12.30**

## **Symposium**

**Chairpersons:**

**25.10.17**

**Conference Hall №3 (D1)**

**13.30–15.00**

**Symposium**

**«Management of cardiovascular risk in patients with diabetes»**

**(supported by Boehringer Ingelheim)**

**Chairperson: Khalimov Y.** (Saint-Petersburg), **Napalkov D.** (Moscow)

**Khalimov Y.** (Saint-Petersburg) New patterns of type 2 DM management: from glucocentric dogma to real organ protection.

**Galstyan G.** (Moscow). EMPA-REG OUTCOME: two years later.

**Napalkov D.** (Moscow). Atrial fibrillation and diabetes mellitus: a complicated clinical combination.

**25.10.17**

**Conference Hall №4 (D2)**

**13.30–15.00**

**Symposium**

**«The Philosopher's Stone of today, or what are the options to slow down ageing?»**

**(supported by Teva)**

**Chairperson: Tkacheva O. (Moscow)**

**Tkacheva O. (Moscow).** Introductory speech. Causes of ageing and possible ways of slowing it down.

**Tkacheva O. (Moscow).** «From metal to gold" or from conventional diuretic therapy to prolonging life.

**Dzgoeva F. (Moscow).** Pharmacological prevention of age-associated diseases.

**Susekov A. (Moscow).** How to prepare an elixir of life from ordinary drugs.

**25.10.17**

**Conference Hall №5 (D3)**

**13.30–15.00**

**Symposium**

**«Latest studies of the clinical practice: primary and secondary prevention»**

**(supported by AstraZeneca)**

**Chairperson: Boitsov S. (Moscow)**

**Boitsov S. (Moscow).** CEPHEUS II: do we achieve our goals in the primary and secondary cardiovascular prevention.

**Karpov Yu. (Moscow).** OPTIMA II and CVD-Real: Statins and anti-hyperglycemic drugs and impact on prognosis.

**Oschepkova E. (Moscow).** STREAM: 1-year dual antiplatelet therapy in the Russian post-ACS population.



**25.10.17**

**Conference Hall №7 (B1)**

**13.30–15.00**

**Symposium**

**«Hot topics in diuretic therapy»**

**(supported by Takeda)**

**Chairpersons: Arutyunov G. (Moscow), Tarlovskaya E. (Nizhny Novgorod)**

**Tarlovskaya E. (Nizhny Novgorod).** Clinical niches for prolonged release diuretics administration.

**Koziołova N. (Perm).** CHF and special clinical situations: how can diuretics help?

**Arutyunov A. (Moscow).** Long-term natriuresis as a strategic goal in diuretic treatment.

**Discussion of experts on difficulties in administration of diuretics in clinical practice.**

**25.10.17**

**Conference Hall №8 (B2)**

**13.30–15.00**

**Symposium**

**«Current option in CHF management: from bench to bedside»**

**(supported by Pfizer)**

**Chairperson: Andreev D. (Moscow)**

**Andreev D. (Moscow).** Patient with CHF after MI: how to improve the prognosis?

**Obrezan A. (Saint-Petersburg).** Patient with CHF and ventricular extrasystole.

**Arutyunov G. (Moscow).** Early start of therapy as the key to successful treatment of a HF patient.

**25.10.17**

**Conference Hall №11 (A4-A5)**

**13.30–15.00**

**Working meeting**

**«RSC 2017»**

**25.10.17**

**Conference Hall №1 (E8-E9)**

**15.30–17.00**

**Symposium**

**«Choice of anticoagulation therapy for the AF patients not mentioned in the guidelines. What can we do for them?»**

**(supported by Bayer)**

**Chairperson: Belenkov Yu. (Moscow)**

**Mareev V. (Moscow).** Venous thromboses: do we know everything of them and what questions are left unanswered?

**Gilyarevsky S. (Moscow).** Evidence-based cardiology and controversial issues in anticoagulation therapy. Clinical pharmacologist perspective.

**Shubik Yu. (Saint-Petersburg).** Non-typical patients in the arrhythmology practice. Case study.

**Take home message.**

**25.10.17**

**Conference Hall №2 (E7)**

**15.30–17.00**

**Symposium**

**«Multidisciplinary approach to management of CHF patients: new horizons and therapy options»  
(supported by Novartis)**

**Chairpersons: Shlyakhto E.** (Saint-Petersburg), **Kobalava Z.** (Moscow)

**Villevalde S.** (Moscow). Cardiovascular continuum in CHF. Focus on prevention of recurrent cardiovascular events.

**Discussion. Shlyakhto E.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Nedoshivin A.** (Saint-Petersburg), **Villevalde S.** (Moscow).

**Kobalava Z.** (Moscow). New areas of ARNI investigation: what is waiting for us in the near future?

**Discussion. Shlyakhto E.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Nedoshivin A.** (Saint-Petersburg), **Villevalde S.** (Moscow).

**Nedoshivin A.** (Saint-Petersburg). Practical aspects of specialized care organization for CFH patients.

**Discussion. Shlyakhto E.** (Saint-Petersburg), **Kobalava Z.** (Moscow), **Nedoshivin A.** (Saint-Petersburg), **Villevalde S.** (Moscow).

**25.10.17**

**Conference Hall №4 (D2)**

**15.30–17.00**

### **Symposium**

**«Endovascular techniques assisting cardiologists: structural heart disease and resistant hypertension»  
(supported by Cardiomedics / Boston Scientific)**

### **Simultaneous translation**

#### **Chairpersons:**

Introduction. Cardiologists do not know or do not want? The problem of referring patients to endovascular procedures available in Russia.

**Georgiou G.** (Cyprus). TAVI: extending horizons.

**Zverev D.** (Saint-Petersburg). TAVI in Russia: implementation in clinical practice, specificities, tactics of patient selection and post-procedural management.

**Davtyan K.** (Moscow). Watchman left atrial appendage occlusion device: latest data on stroke prevention in AF patients from EWOLUTION registry. Selection of optimal candidate and tactic of post-procedural antithrombotic therapy.

**Pavlov P.** (Khanty-Mansijsk). How to treat a patient with resistant hypertension? Renal denervation: results in Russia, selection of optimal category of patients.

**Mikhaylov E.** (Saint-Petersburg). Beyond resistant hypertension: does renal denervation affect other conditions associated with sympathetic hyperactivation?

**Discussion.**

**25.10.17**

**Conference Hall №5 (D3)**

**15.30–17.00**

**Symposium**

**«Current approaches to CHF treatment»**

**(supported by Akrikhin)**

**Chairpersons: Arutyunov G. (Moscow), Ageev F. (Moscow), Mareev V. (Moscow)**

**Mareev V. (Moscow).** Advantages and disadvantages of mineralocorticoid receptor antagonists for CHF.

**Arutyunov G. (Moscow).** How to save cognitive function in a cardiovascular patient?

**Ageev F. (Moscow).** Choice of therapy for CHF with preserved LV ejection fraction.

**25.10.17**

**Conference Hall №6 (D4)**

**15.30–17.00**

**Symposium**

**«Polypharmacy or Pharmageddon of our time?»**

**(supported by Gedeon Richter)**

**Chairperson: Lopatin Yu. (Volgograd)**

**Nedogoda S. (Volgograd).** Comorbidity and polypharmacy: prescribe never cancel.

**Tkacheva O. (Moscow).** Gerontology practice: when a patient is enthralled by drug illusions.

**Lopatin Yu. (Volgograd).** Discussion.



**25.10.17**

**Conference Hall №8 (B2)**

**15.30–17.00**

**Symposium**

**«Pulmonary arterial hypertension: current understanding of the problem»**

**(supported by Pfizer)**

**On-line broadcasting**

**Chairpersons: Moiseeva O.** (Saint-Petersburg), **Martyniuk T.** (Moscow)

**Moiseeva O.** (Saint-Petersburg). PAH: a way from the first symptoms to specialized care.

**Martyniuk T.** (Moscow). Basic principles of PAH treatment. Sildenafil in guidelines and clinical practice.

**Simakova M.** (Saint-Petersburg). Clinical cases of PAH patients.

**26.10.17**

**Conference Hall №5 (D3)**

**11.00–12.30**

**Symposium**

**«A journey through the time: from Leonardo Da Vinci to our days»**

**(supported by Gedeon Richter)**

**Chairperson: Ageev F. (Moscow)**

**Drapkina O.** (Moscow). The perfect components of the combination as a guarantee of the therapy success.

**Ageev F.** (Moscow). High and very high risk patients: do we use every possibility? ALROSA study results.

**Averin E.** (Moscow). What is classic and what is new in the treatment of chronic heart failure?

**26.10.17**

**Conference Hall №7 (B1)**

**11.00–12.30**

**Symposium**

**«Long-term double anti-platelet therapy in patients after myocardial infarction: how long and to whom?»**

**(supported by AstraZeneca)**

**Chairperson: Ruda M.** (Moscow)

**Barbarash O.** (Kemerovo). DAT in ACS patients in clinical practice.

**Panchenko E.** (Moscow). High cardiovascular risk a year after MI and how to reduce it: PEGASUS results.

**Averkov O.** (Moscow). Choosing a patient: who needs long-term DAT?

**26.10.17**

**Conference Hall №8 (B2)**

**13.30–15.00**

**Symposium**

**«Historic parallels: Polypill in the concept of new science of power by Machiavelli»**

**(supported by Gedeon Richter)**

**Chairperson: Arutyunov G. (Moscow)**

**Arutyunov G. (Moscow).** Management of cardiovascular risks: antihypertensive therapy perspective.

**Arutyunov A. (Moscow).** Management of cardiovascular risks: lipid-lowering therapy perspective.

**Arutyunov G. (Moscow), Arutyunov A. (Moscow).** Discussion: Therapy onset: the sooner, the better? Indications for early start of statin therapy.